Tevogen signs letter of intent to evaluate CRO acquisition

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it has signed a non-exclusive, non-binding letter of intent to evaluate a potential acquisition of a global contract research organization.

The Warren, New Jersey-based company stated the proposed transaction could expand its clinical development capabilities and support its evolution into a revenue-generating healthcare enterprise, according to a press release.

"The potential acquisition of a CRO could introduce revenue-generating service capabilities while allowing us to optimize trial execution internally," said Dr. Ryan Saadi, founder and chief executive officer of Tevogen. "We believe this combination of operational control and service revenue may strengthen earnings visibility, support a more capital-efficient growth model, and enhance patient affordability."

The proposed transaction remains subject to completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions.

Tevogen stated it is also actively considering other transactions focused on life sciences-related businesses, though the company noted there is no assurance any such transaction will be completed.

The company operates as a healthcare enterprise that leverages artificial intelligence and precision T cell therapy platforms. Its lead initiative, Tevogen Bio, has completed a proof-of-concept clinical trial for single-HLA-restricted, genetically unmodified allogeneic T cells with programs spanning virology, oncology, and neurology.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Isabella Bank to acquire Grand River Commerce for $54.6 million
• Mistral AI in talks to raise funds at €20b valuation - Bloomberg